Please login to the form below

Not currently logged in
Email:
Password:

BACE inhibitors

This page shows the latest BACE inhibitors news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Off BACE: AZ/Lilly drop Alzheimer’ s drug lanabecestat. AstraZeneca and Eli Lilly have abandoned their Alzheimer’s drug candidate lanabecestat after an interim look at phase III data suggested there ... It’s also another blow to the

Latest news

More from news
Approximately 2 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    we need more data on the efficacy of other approaches, including beta secretase cleaving enzyme (BACE) inhibitors which may reduce amyloid formation, rather than targeting its removal like the antibody strategies.”. ... Big pharma backing BACE. A

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics